Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Oct 4 - Oct 9
Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(736) amide in type 2 (non-insulin-dependent) diabetic patients
GLP 1 Medications and Eating Disorders: What Are GLP-1 Medications
Use CODE OTP25 to save 25%
Safety signals identified through extended follow-up include: Gastrointestinal effects : Nausea, vomiting, and diarrhea remain the most common adverse events, typically diminishing over time but causing discontinuation in approximately 57% of patients Gallbladder disease : Increased incidence of cholelithiasis and cholecystitis, possibly associated with weight loss, though the exact mechanism remains under investigation Diabetic retinopathy : Risk of complications, particularly with rapid glycemic improvement in patients with pre-existing retinopathy Acute kidney injury : Risk associated with severe gastrointestinal adverse events leading to dehydration Pancreatitis : Rare cases reported, though causality remains uncertain
G0/G1 switch gene 2 regulates cardiac lipolysis
